Plant Comparison
Andrographis vs Purple coneflower
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Andrographis and Purple coneflower: they share 7 indicated uses (arthritis / joint pain, cold & flu, immune support, …); 3 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Andrographis | Purple coneflower | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 1/10 | Stronger for Andrographis |
| Cold & flu | 8/10 | 1/10 | Stronger for Andrographis |
| Immune support | 5/10 | 1/10 | Stronger for Andrographis |
| Infection (general) | 8/10 | 1/10 | Stronger for Andrographis |
| Inflammation (general) | 5/10 | 1/10 | Stronger for Andrographis |
| Skin irritation | 5/10 | 1/10 | Stronger for Andrographis |
| Wounds | 5/10 | 1/10 | Stronger for Andrographis |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Lipophilic alkamides are considered key immunomodulatory and anti-inflammatory constituents, particularly concentrated in the root.
Antioxidant phenolic compounds contributing to the plant's immunomodulatory activity.
Water-soluble polysaccharides associated with immune-stimulating activity, particularly from the aerial parts.
Pharmacological Actions
Andrographolide, the principal diterpene lactone of Andrographis paniculata, suppresses proliferation and induces apoptosis across breast, lung, colon, cervical, hepatic and haematological cancers via NF-kappaB and PI3K/Akt inhibition (preclinical).
Traditional & Indicated Uses
inferred from anti-inflammatory action
Andrographolide (from Andrographis paniculata) acts as a chemopreventive and antitumour agent against breast, lung, colorectal, cervical, prostate and hepatocellular cancers and leukaemia, inducing apoptosis and inhibiting NF-kappaB and PI3K/AKT signalling (preclinical).
Symptomatic relief of the common cold and acute upper respiratory tract infection (reduces symptom severity and duration)
Immunostimulant / immune support
Symptomatic relief of the common cold and acute upper respiratory tract infection (reduces symptom severity and duration)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Avoid in pregnancy and when trying to conceive: high doses have shown reproductive toxicity in animals and the herb has a traditional reputation as an abortifacient.
High doses have caused nephrotoxicity and reproductive toxicity in studies; use standardized products at recommended doses and avoid prolonged high-dose use.
Generally considered safe, but caution advised for those with autoimmune conditions. Not recommended for long-term use (more than 8 weeks continuously).
Duke (2002) rates echinacea as +++ — among the most thoroughly documented herbal immunostimulants. It notes experimental and clinical evidence for immunostimulant, antiviral, and anti-inflammatory activities. Multiple species have been studied (E. purpurea, E. angustifolia, E. pallida), and Duke emphasizes that species identification in commercial products is often unreliable. Commission E approves E. purpurea for supporting immune function during colds and flu. Dose: 900 mg standardized extract daily in acute use; use should be limited to 8 weeks continuous. Contraindicated in autoimmune diseases (MS, lupus, HIV/AIDS), tuberculosis, and with immunosuppressive drugs (cyclosporine) (Duke, 2002).
External Ids
Botanical Description
Erect, branching annual herb with a slender, quadrangular (square-sectioned), dark green stem. The leaves are opposite, lance-shaped and glabrous, with a short stalk. Small, two-lipped, white flowers with purple-pink markings are borne in loose, spreading axillary and terminal racemes. The whole plant, and especially the leaves, is intensely and characteristically bitter.[11]
Robust perennial herb with a basal rosette of coarse, hairy, lance-shaped leaves and tall, sturdy flowering stems. Each stem bears a single large, daisy-like flower head with drooping (reflexed), rose-purple to pink ray florets surrounding a prominent, spiny, orange-brown central cone of disc florets.[4]
Habitat
Native to India and Sri Lanka and widely distributed through South and Southeast Asia, growing wild in plains, hillsides, roadsides and cultivated fields; also grown commercially as a medicinal crop.[11]
Native to the tallgrass prairies, open woodland and dry meadows of central and eastern North America; widely cultivated worldwide as a garden and medicinal plant.[4]
Harvesting
The aerial parts (leaves and tender stems) are cut just before or at the onset of flowering, when andrographolide content is typically highest, and dried in shade to preserve the bitter diterpenoid lactones.[11]
The flower heads are picked as they open, in summer; the root is dug in autumn from plants at least two to three years old, when its content of bioactive alkamides and caffeic acid derivatives is highest, then cleaned and dried.[4]
Traditional Uses
Andrographis, the 'king of bitters', is a cornerstone bitter tonic of Ayurvedic and traditional Chinese medicine (Chuan xin lian), used for fevers, colds, sore throat, infections and liver complaints. This traditional reputation for treating the common cold and upper respiratory infections is now supported by clinical trials of standardised extracts.[10, 12]
Echinacea root was widely used by Native American peoples as a remedy for infections, wounds, snakebite and toothache, and entered nineteenth-century Eclectic medicine as a broad anti-infective. It remains best known today, in standardised aerial-part or root extracts, as a supportive remedy for preventing and shortening the common cold and supporting immune function.[1, 4]
Preparations
Dried aerial parts infused or lightly decocted in hot water as a very bitter traditional fever and cold remedy.
Fresh-pressed juice or standardised extract of the aerial parts or root, taken as tablets, drops or capsules at the first sign of a cold; the best-studied clinical form.
Dosage
Clinical trials for upper respiratory infection commonly use extracts standardised to around 60-120 mg andrographolide daily, in divided doses, for up to 5-7 days. Educational reference only, not a prescription.
The WHO monograph on Herba Andrographidis gives, by indication - for the common cold, 1.5-3.0 g of the powdered crude drug three times daily, after meals and at bedtime; for pyrexia, a decoction from 3 g of the crude drug twice daily; for diarrhoea, a decoction from 3-9 g as a single dose as needed, or two 500 mg tablets four times daily. Note that the EMA HMPC assessed this herb and issued a public statement rather than a monograph, so there is no EU posology. Educational reference only, not a prescription.
Clinical trials for the common cold commonly use around 300-900 mg of standardised extract daily, started at the first sign of symptoms and continued for up to 7-10 days; continuous use beyond about 8 weeks is not recommended. Educational reference only, not a prescription.
References
Lookalikes Review
Drug Class Interactions
Not documented
References & Sources
- Okonogi, R. and others (2023) 'Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial', Drug Discoveries & Therapeutics, 17(5), pp. 315-321. doi:10.5582/ddt.2023.01053 Randomized trial
https://doi.org/10.5582/ddt.2023.01053 - Hossain, S., Urbi, Z., Karuniawati, H., Mohiuddin, R.B. and others (2018) 'Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide', Critical Reviews in Food Science and Nutrition, 61(10), pp. 1635-1652. doi:10.1080/10408398.2018.1501657 Meta-analysis / review
https://doi.org/10.1080/10408398.2018.1501657 - Worakunphanich, W. and others (2021) 'Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability', European Journal of Drug Metabolism and Pharmacokinetics, 46(5), pp. 565-581. doi:10.1007/s13318-021-00736-7 Meta-analysis / review
https://doi.org/10.1007/s13318-021-00736-7 - Worakunphanich, W., Thavorncharoensap, M., Youngkong, S., Thakkinstian, A. and Chaikledkaew, U (2021) 'Safety of Andrographis paniculata: A systematic review and meta-analysis', Pharmacoepidemiology and Drug Safety, 30(6), pp. 727-739. doi:10.1002/pds.5190 Meta-analysis / review
https://doi.org/10.1002/pds.5190 - Kumar, S., Singh, B. and Bajpai, V (2021) 'Andrographis paniculata (Burm.f.) Nees and its major constituent andrographolide as potential antiviral agents', Journal of Ethnopharmacology, 274, pp. 113954. doi:10.1016/j.jep.2021.113954 Meta-analysis / review
https://doi.org/10.1016/j.jep.2021.113954 - Barbosa, F.L. and others (2021) 'Andrographis paniculata (Burm. f.) Wall. ex Nees: An Updated Review of Phytochemistry, Antimicrobial Pharmacology, and Clinical Safety and Efficacy', Life, 11(4), pp. 348. doi:10.3390/life11040348 Meta-analysis / review
https://doi.org/10.3390/life11040348 - Singh, P. and others (2022) 'Andrographis paniculata mitigates first-line anti-tubercular drugs-induced nephrotoxicity in Wistar rats', Biomarkers, 27(4), pp. 385-394. doi:10.1080/1354750X.2022.2043444 Preclinical
https://doi.org/10.1080/1354750X.2022.2043444 - Coon, J.T. and Ernst, E (2004) 'Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials', Journal of Clinical Pharmacy and Therapeutics, 29(1), pp. 37-45. doi:10.1046/j.1365-2710.2003.00534.x Meta-analysis / review
https://doi.org/10.1046/j.1365-2710.2003.00534.x - Rondee, N. and others (2023) 'The Effects of Andrographis paniculata (Burm.F.) Wall. Ex Nees and Andrographolide on Neuroinflammation in the Treatment of Neurodegenerative Diseases', Nutrients, 15(15), pp. 3428. doi:10.3390/nu15153428 Meta-analysis / review
https://doi.org/10.3390/nu15153428 - Zeng, B., Wei, A., Zhou, Q., Yuan, M., Lei, K., Liu, Y., Song, J., Guo, L. and Ye, Q (2021) 'Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches', Phytotherapy Research. doi:10.1002/ptr.7324 Randomized trial
https://doi.org/10.1002/ptr.7324 - Gonde, D.P., Bhole, B.K. and Kakad, K.S (2023) 'Andrographolide, diterpenoid constituent of Andrographis paniculata: Review on botany, phytochemistry, molecular docking analysis, and pharmacology', Annales Pharmaceutiques Francaises. doi:10.1016/j.pharma.2023.10.001 Preclinical
https://doi.org/10.1016/j.pharma.2023.10.001 - Hu, X.Y., Wu, R.H., Logue, M., Blondel, C., Lai, L.Y.W., Stuart, B., Flower, A., Fei, Y.T., Moore, M., Shepherd, J., Liu, J.P. and Lewith, G (2017) 'Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis', PLoS ONE. doi:10.1371/journal.pone.0181780 Meta-analysis / review
https://doi.org/10.1371/journal.pone.0181780 - World Health Organization (2002) 'Herba Andrographidis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Tundis, R. and Patra, J.K. and Bonesi, M. and Das, S. and Nath, R. and Das Talukdar, A. and Das, G. and Loizzo, M.R (2023) 'Anti-Cancer Agent: The Labdane Diterpenoid-Andrographolide', Plants, 12(10), pp. 1969. doi:10.3390/plants12101969 Preclinical
https://doi.org/10.3390/plants12101969 - Mishra, S.K. and Tripathi, S. and Shukla, A. and Oh, S.H. and Kim, H.M (2015) 'Andrographolide and analogues in cancer prevention', Frontiers in Bioscience (Elite Edition), 7(2), pp. 255-266. doi:10.2741/E732 Preclinical
https://doi.org/10.2741/E732 - Paul, S. and Roy, D. and Pati, S. and Sa, G (2021) 'The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer', Frontiers in Pharmacology, 12, pp. 731492. doi:10.3389/fphar.2021.731492 Preclinical
https://doi.org/10.3389/fphar.2021.731492 - Memorial Sloan Kettering Cancer Center (n.d.) 'Andrographis (About Herbs)'. Available at: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/andrographis Traditional / reference
https://www.mskcc.org/cancer-care/integrative-medicine/herbs/andrographis
- Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R. et al (2014) 'Echinacea for preventing and treating the common cold', Cochrane Database of Systematic Reviews, 2(2), pp. CD000530. doi:10.1002/14651858.CD000530.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD000530.pub3 - Kamin, W., Seifert, G., Zwiauer, K., Bonhoeffer, J. et al (2025) 'Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review', Frontiers in Pediatrics, 13, pp. 1423250. doi:10.3389/fped.2025.1423250 Meta-analysis / review
https://doi.org/10.3389/fped.2025.1423250 - Fashner, J., Ericson, K. and Werner, S (2012) 'Treatment of the common cold in children and adults', American Family Physician, 86(2), pp. 153-159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22962927/ - Manayi, A., Vazirian, M. and Saeidnia, S (2015) 'Echinacea purpurea: Pharmacology, phytochemistry and analysis methods', Pharmacognosy Reviews, 9(17), pp. 63-72. doi:10.4103/0973-7847.156353 Meta-analysis / review
https://doi.org/10.4103/0973-7847.156353 - Burlou-Nagy, C., Banica, F., Jurca, T., Vicas, L.G., Marian, E., Muresan, M.E., Bacskay, I., Kiss, R., Feher, P. and Pallag, A (2022) 'Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review', Plants, 11(9), pp. 1244. doi:10.3390/plants11091244 Meta-analysis / review
https://doi.org/10.3390/plants11091244 - Hall, H., Fahlman, M.M. and Engels, H.J (2007) 'Echinacea purpurea and mucosal immunity', International Journal of Sports Medicine, 28(9), pp. 792-797. doi:10.1055/s-2007-964895 Randomized trial
https://doi.org/10.1055/s-2007-964895 - Ross, S.M (2016) 'Echinacea purpurea: A Proprietary Extract of Echinacea purpurea Is Shown to be Safe and Effective in the Prevention of the Common Cold', Holistic Nursing Practice, 30(1), pp. 54-57. doi:10.1097/HNP.0000000000000130 Meta-analysis / review
https://doi.org/10.1097/HNP.0000000000000130 - Hudson, J.B (2011) 'Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases', Journal of Biomedicine & Biotechnology, 2012, pp. 769896. doi:10.1155/2012/769896 Meta-analysis / review
https://doi.org/10.1155/2012/769896 - Mishima, S., Saito, K., Maruyama, H., Inoue, M., Yamashita, T., Ishida, T. and Gu, Y (2004) 'Antioxidant and immuno-enhancing effects of Echinacea purpurea', Biological & Pharmaceutical Bulletin, 27(7), pp. 1004-1009. doi:10.1248/bpb.27.1004 Preclinical
https://doi.org/10.1248/bpb.27.1004 - Saunders, P.R., Smith, F. and Schusky, R.W (2007) 'Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections', Canadian Journal of Physiology and Pharmacology, 85(11), pp. 1195-1199. doi:10.1139/Y07-103 Clinical study
https://doi.org/10.1139/Y07-103 - Micheli, L., Maggini, V., Ciampi, C., Gallo, E., Bogani, P., Fani, R., Pistelli, L., Ghelardini, C., Di Cesare Mannelli, L., De Leo, M. and Firenzuoli, F (2022) 'Echinacea purpurea against neuropathic pain: Alkamides versus polyphenols efficacy', Phytotherapy Research, 37(5), pp. 1911-1923. doi:10.1002/ptr.7709 Preclinical
https://doi.org/10.1002/ptr.7709 - Gholami, M., Amri, J., Pazhoohan, S. and Sadegh, M (2021) 'Anticonvulsive and anti-epileptogenesis effects of Echinacea purpurea root extract, an involvement of CB2 receptor', Journal of Complementary & Integrative Medicine, 19(4), pp. 879-886. doi:10.1515/jcim-2020-0219 Preclinical
https://doi.org/10.1515/jcim-2020-0219 - Awortwe, C., Bruckmueller, H., Kaehler, M. and Cascorbi, I (2021) 'Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters', Molecular Pharmaceutics, 18(4), pp. 1622-1633. doi:10.1021/acs.molpharmaceut.0c01075 Preclinical
https://doi.org/10.1021/acs.molpharmaceut.0c01075 - Perry, N.B., van Klink, J.W., Burgess, E.J. and Parmenter, G.A (1997) 'Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers', Planta Medica, 63(1), pp. 58-62. doi:10.1055/s-2006-957605 Preclinical
https://doi.org/10.1055/s-2006-957605 - Linde, K., Barrett, B., Wölkart, K., Bauer, R. and Melchart, D (2006) 'Echinacea for preventing and treating the common cold'. Traditional / reference
https://scholar.google.com/scholar?q=Echinacea%20for%20preventing%20and%20treating%20the%20common%20cold - Sharma, M., Schoop, R., Suter, A. and Schoop, W (2010) 'The possibility of prophylactic treatment of streptococcal pharyngotonsillitis with a standardized Echinacea preparation', 29(8), pp. 1025--1035. Traditional / reference
https://scholar.google.com/scholar?q=The%20possibility%20of%20prophylactic%20treatment%20of%20streptococcal%20pharyngotonsillitis%20with%20a%20standardized%20Echinacea%20preparation - World Health Organization (1999) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
https://scholar.google.com/scholar?q=WHO%20Monographs%20on%20Selected%20Medicinal%20Plants - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Gorski, J.C., Huang, S.M., Pinto, A., Hamman, M.A., Hilligoss, J.K., Zaheer, N.A., Desai, M., Miller, M. and Hall, S.D (2004) 'The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo', Clinical Pharmacology and Therapeutics, 75(1), pp. 89-100. doi:10.1016/j.clpt.2003.09.013 Clinical study
https://doi.org/10.1016/j.clpt.2003.09.013
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.